Biotech and Pharmaceuticals
Danaher had a disappointing 2024. Its path to success next year goes through Wall Street
Life sciences firm Danaher has certainly not been an easy stock to own this year. A wave of startups going public on Wall Street would go a long ways toward changing that. Year-to-date performance: down 0.1% Forward price-to-earnings multiple: 27.8 versus a five-year average of 28.8 Our rating: Buy-equivalent 1 Our price target: $305 a […]
Read More
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters The roughly $1,000 monthly price tag of Eli Lilly‘s weight loss drug Zepbound put the blockbuster treatment out of reach for Willow Baillies, 29, whose insurance does not cover it. Baillies, […]
Read More
The ‘weight-loss trade’ has stalled. What it will take to revive investor interest
Anyone who’s been on a diet can likely relate: Those first lost pounds are met with a sense of euphoria. The voice inside one’s head screams: “I’ve got this!” But then, it inevitably becomes a slog. The initial novelty wears off, and the real work begins. Investors may see a parallel to the initial elation […]
Read More
Eli Lilly looks to extend its winning streak over the broader market to 6 years
Eli Lilly has outperformed the S & P 500 for five straight years as Wall Street woke up to its massive opportunity in obesity drugs. Six in a row is not out of the question. Year-to-date performance: Up 33.7% Forward price-to-earnings ratio: 34.3 versus five-year average of 34.5 Our rating: Buy-equivalent 1 Our price target: […]
Read More
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea, expanding use in U.S.
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Shelby Knowles | Bloomberg | Getty Images The Food and Drug Administration approved Eli Lilly‘s blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, the drugmaker announced […]
Read More
Novo Nordisk shares plunge 19% after disappointing trial results; Lilly jumps in premarket
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Hollie Adams | Reuters Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting results in a late-stage trial for its experimental CagriSema weight loss drug that missed expectations. The maker of the […]
Read More
FDA says Eli Lilly’s weight loss drug Zepbound is no longer in shortage
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters The Food and Drug Administration on Thursday said the active ingredient in Eli Lilly’s weight loss drug Zepbound is no longer in shortage, a decision that will eventually bar compounding pharmacies […]
Read More
Why Americans are outraged over health insurance — and what could change
A person holds a sign while standing on the roadside near the McDonald’s restaurant where a suspect in the killing of the CEO of UnitedHealthcare, Brian Thompson, identified as Luigi Mangione, 26, was arrested, in Altoona, Pennsylvania, U.S. December 9, 2024. Matthew Hatcher | Reuters The deadly, targeted shooting of UnitedHealthcare CEO Brian Thompson has […]
Read More
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Exterior view of the entrance to Merck headquarters on February 05, 2024 in Rahway, New Jersey. Spencer Platt | Getty Images Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. The oral drug has not yet […]
Read More
Healthy Returns: Novo Nordisk’s Ozempic faces scrutiny over potential link to rare eye condition
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. There may be a […]
Read More